Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques
Article Abstract:
The primary cause of severe acute respiratory syndrome (SARS) is a newly discovered corona-virus. Also shown is that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-alpha (IFN-alpha) significantly reduces viral replication. Therefore pegylated IFN-alpha protects type 1 pneumocytes from SCV infection and should be considered a candidate drug for SARS therapy.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Antibiotics- An investment worth making?
Article Abstract:
The combination of significantly increased regulatory risk and shrinking margins make it tough for investors to continue investment in antibiotic research and development, due to which, venture capital investors are showing greater caution. A study explores the problems facing the field and discusses some ways of solving them.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Identification of a new human coronavirus
Article Abstract:
A fourth human coronavirus, HCOV-NL63, is identified after screening individuals having respiratory illnesses. A detailed description of this HCOV-NL63 virus is presented.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
- Abstracts: Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions. Hepatocyte transplantation in a model of toxin-induced liver disease: variable therapeutic effect during replacement of damaged parenchyma by donor cells
- Abstracts: One enzyme inactivates two antibiotics. Keeping the fat off with nesfatin
- Abstracts: Drug companies accused of stalling tailored therapies. European scientists push spinal taps for Alzheimer diagnosis